<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">35079804</PMID><DateCompleted><Year>2022</Year><Month>06</Month><Day>17</Day></DateCompleted><DateRevised><Year>2022</Year><Month>12</Month><Day>07</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1537-6613</ISSN><JournalIssue CitedMedium="Internet"><Volume>225</Volume><Issue>12</Issue><PubDate><Year>2022</Year><Month>Jun</Month><Day>15</Day></PubDate></JournalIssue><Title>The Journal of infectious diseases</Title><ISOAbbreviation>J Infect Dis</ISOAbbreviation></Journal><ArticleTitle>Persistent Autoimmune Activation and Proinflammatory State in Post-Coronavirus Disease 2019 Syndrome.</ArticleTitle><Pagination><StartPage>2155</StartPage><EndPage>2162</EndPage><MedlinePgn>2155-2162</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">jiac017</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1093/infdis/jiac017</ELocationID><Abstract><AbstractText Label="BACKGROUND">The immunopathological pathways enabling post-coronavirus disease 2019 (COVID-19) syndrome (PCS) development are not entirely known. We underwent a longitudinal analysis of patients with COVID-19 who developed PCS aiming to evaluate the autoimmune and immunological status associated with this condition.</AbstractText><AbstractText Label="METHODS">Thirty-three patients were included for longitudinal clinical and autoantibody analyses, 12 of whom were assessed for cytokines and lymphocyte populations. Patients were followed for 7-11 months after acute COVID-19. Autoimmune profile and immunological statuses were evaluated mainly by enzyme-linked-immunosorbent assays and flow cytometry.</AbstractText><AbstractText Label="RESULTS">Latent autoimmunity and overt autoimmunity persisted over time. A proinflammatory state was observed in patients with PCS characterized by up-regulated interferon-&#x3b1;, tumor necrosis factor-&#x3b1;, granulocyte colony-stimulating factor (G-CSF), interleukin (IL)-17A, IL-6, IL-1&#x3b2;, and IL-13, whereas interferon-&#x3b3;-induced protein 10 (IP-10) was decreased. In addition, PCS was characterized by increased levels of Th9, CD8+ effector T cells, naive B cells, and CD4+ effector memory T cells. Total levels of immunoglobulin G S1-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies remained elevated over time.</AbstractText><AbstractText Label="CONCLUSIONS">The clinical manifestations of PCS are associated with the persistence of a proinflammatory and effector phenotype induced by SARS-CoV-2 infection. This long-term persistent immune activation may contribute to the development of latent and overt autoimmunity. Results suggest the need to evaluate the role of immunomodulation in the treatment of PCS.</AbstractText><CopyrightInformation>&#xa9; The Author(s) 2022. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Acosta-Ampudia</LastName><ForeName>Yeny</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Center for Autoimmune Diseases Research (CREA), School of Medicine and Health Sciences, Universidad del Rosario, Bogota, Colombia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Monsalve</LastName><ForeName>Diana M</ForeName><Initials>DM</Initials><AffiliationInfo><Affiliation>Center for Autoimmune Diseases Research (CREA), School of Medicine and Health Sciences, Universidad del Rosario, Bogota, Colombia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rojas</LastName><ForeName>Manuel</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-8604-4658</Identifier><AffiliationInfo><Affiliation>Center for Autoimmune Diseases Research (CREA), School of Medicine and Health Sciences, Universidad del Rosario, Bogota, Colombia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rodr&#xed;guez</LastName><ForeName>Yhojan</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Center for Autoimmune Diseases Research (CREA), School of Medicine and Health Sciences, Universidad del Rosario, Bogota, Colombia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Cl&#xed;nica del Occidente, Bogota, Colombia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zapata</LastName><ForeName>Elizabeth</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Center for Autoimmune Diseases Research (CREA), School of Medicine and Health Sciences, Universidad del Rosario, Bogota, Colombia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ram&#xed;rez-Santana</LastName><ForeName>Carolina</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Center for Autoimmune Diseases Research (CREA), School of Medicine and Health Sciences, Universidad del Rosario, Bogota, Colombia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Anaya</LastName><ForeName>Juan-Manuel</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Center for Autoimmune Diseases Research (CREA), School of Medicine and Health Sciences, Universidad del Rosario, Bogota, Colombia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Cl&#xed;nica del Occidente, Bogota, Colombia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Infect Dis</MedlineTA><NlmUniqueID>0413675</NlmUniqueID><ISSNLinking>0022-1899</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016207">Cytokines</NameOfSubstance></Chemical><Chemical><RegistryNumber>82115-62-6</RegistryNumber><NameOfSubstance UI="D007371">Interferon-gamma</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>J Infect Dis. 2022 Sep 4;226(4):751-752. doi: 10.1093/infdis/jiac105</RefSource><PMID Version="1">35313338</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>J Infect Dis. 2022 Sep 4;226(4):753-754. doi: 10.1093/infdis/jiac106</RefSource><PMID Version="1">35313345</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D015551" MajorTopicYN="Y">Autoimmunity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016207" MajorTopicYN="N">Cytokines</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007249" MajorTopicYN="N">Inflammation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007371" MajorTopicYN="N">Interferon-gamma</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">autoimmunity</Keyword><Keyword MajorTopicYN="N">long COVID</Keyword><Keyword MajorTopicYN="N">naive B cells</Keyword><Keyword MajorTopicYN="N">post-COVID syndrome</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>11</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>1</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>1</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>6</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>1</Month><Day>26</Day><Hour>5</Hour><Minute>32</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>1</Month><Day>25</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35079804</ArticleId><ArticleId IdType="pmc">PMC8903340</ArticleId><ArticleId IdType="doi">10.1093/infdis/jiac017</ArticleId><ArticleId IdType="pii">6515371</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Dhama K, Khan S, Tiwari R, et al. . Coronavirus disease 2019&#x2013;COVID-19. Clin Microbiol Rev 2020; 33:e00028&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7405836</ArticleId><ArticleId IdType="pubmed">32580969</ArticleId></ArticleIdList></Reference><Reference><Citation>Anaya J-M, Rojas M, Salinas ML, et al. . Post-COVID syndrome. A case series and comprehensive review. Autoimmun Rev 2021; 20:102947.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8428988</ArticleId><ArticleId IdType="pubmed">34509649</ArticleId></ArticleIdList></Reference><Reference><Citation>Jacobs JJL. Persistent SARS-2 infections contribute to long COVID-19. Med Hypotheses 2021; 149:110538.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7884250</ArticleId><ArticleId IdType="pubmed">33621843</ArticleId></ArticleIdList></Reference><Reference><Citation>Mongio&#xec; LM, Barbagallo F, Condorelli RA, et al. . Possible long-term endocrine-metabolic complications in COVID-19: lesson from the SARS model. Endocrine 2020; 68:467&#x2013;70.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7266418</ArticleId><ArticleId IdType="pubmed">32488837</ArticleId></ArticleIdList></Reference><Reference><Citation>Fogarty H, Townsend L, Morrin H, et al. . Persistent endotheliopathy in the pathogenesis of long COVID syndrome. J Thromb Haemost 2021; 19:2546&#x2013;53.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8420256</ArticleId><ArticleId IdType="pubmed">34375505</ArticleId></ArticleIdList></Reference><Reference><Citation>Ca&#xf1;as CA. The triggering of post-COVID-19 autoimmunity phenomena could be associated with both transient immunosuppression and an inappropriate form of immune reconstitution in susceptible individuals. Med Hypotheses 2020; 145:110345.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7556280</ArticleId><ArticleId IdType="pubmed">33080459</ArticleId></ArticleIdList></Reference><Reference><Citation>Tserel L, J&#xf5;gi P, Naaber P, et al. . Long-term elevated inflammatory protein levels in asymptomatic SARS-CoV-2 infected individuals. Front Immunol 2021; 12:709759.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8484961</ArticleId><ArticleId IdType="pubmed">34603283</ArticleId></ArticleIdList></Reference><Reference><Citation>Acosta-Ampudia Y, Monsalve DM, Rojas M, et al. . COVID-19 convalescent plasma composition and immunological effects in severe patients. J Autoimmun 2021; 118:102598.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7826092</ArticleId><ArticleId IdType="pubmed">33524876</ArticleId></ArticleIdList></Reference><Reference><Citation>Anaya J-M, Monsalve DM, Rojas M, et al. . Latent rheumatic, thyroid and phospholipid autoimmunity in hospitalized patients with COVID-19. J Transl Autoimmun 2021; 4:100091.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7920824</ArticleId><ArticleId IdType="pubmed">33681751</ArticleId></ArticleIdList></Reference><Reference><Citation>Pacheco Y, Barahona-Correa J, Monsalve DM, et al. . Cytokine and autoantibody clusters interaction in systemic lupus erythematosus. J Transl Med 2017; 15:239.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5702157</ArticleId><ArticleId IdType="pubmed">29178890</ArticleId></ArticleIdList></Reference><Reference><Citation>Wajnberg A, Amanat F, Firpo A, et al. . Robust neutralizing antibodies to SARS-CoV-2 infection persist for months. Science 2020; 370:1227&#x2013;30.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7810037</ArticleId><ArticleId IdType="pubmed">33115920</ArticleId></ArticleIdList></Reference><Reference><Citation>Iyer AS, Jones FK, Nodoushani A, et al. . Persistence and decay of human antibody responses to the receptor binding domain of SARS-CoV-2 spike protein in COVID-19 patients. Sci Immunol 2020; 5:eabe0367.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7857394</ArticleId><ArticleId IdType="pubmed">33033172</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen J, Xiaomin L, Zhang X, et al. . Decline in neutralising antibody responses, but sustained T-cell immunity, in COVID-19 patients at 7 months post-infection. Clin Transl Immunol 2021; 10:e1319.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8313961</ArticleId><ArticleId IdType="pubmed">34336207</ArticleId></ArticleIdList></Reference><Reference><Citation>Ivanov A, Semenova E.. Long-term monitoring of the development and extinction of IgA and IgG responses to SARS-CoV-2 infection. J Med Virol 2021; 93:5953&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8426671</ArticleId><ArticleId IdType="pubmed">34185312</ArticleId></ArticleIdList></Reference><Reference><Citation>Knight JS, Caricchio R, Casanova J-L, et al. . The intersection of COVID-19 and autoimmunity. J Clin Invest 2021; 131:e154886.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8670833</ArticleId><ArticleId IdType="pubmed">34710063</ArticleId></ArticleIdList></Reference><Reference><Citation>Bertin D, Kaphan E, Weber S, et al. . Persistent IgG anticardiolipin autoantibodies are associated with post-COVID syndrome. Int J Infect Dis 2021; 113:23&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8487460</ArticleId><ArticleId IdType="pubmed">34614444</ArticleId></ArticleIdList></Reference><Reference><Citation>See&#xdf;le J, Waterboer T, Hippchen T, et al. . Persistent symptoms in adult patients one year after COVID-19: a prospective cohort study. Clin Infect Dis 2021:ciab611. doi: 10.1093/cid/ciab611.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciab611</ArticleId><ArticleId IdType="pmc">PMC8394862</ArticleId><ArticleId IdType="pubmed">34223884</ArticleId></ArticleIdList></Reference><Reference><Citation>Tipton CM, Fucile CF, Darce J, et al. . Diversity, cellular origin and autoreactivity of antibody-secreting cell population expansions in acute systemic lupus erythematosus. Nat Immunol 2015; 16:755&#x2013;65.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4512288</ArticleId><ArticleId IdType="pubmed">26006014</ArticleId></ArticleIdList></Reference><Reference><Citation>Jenks SA, Cashman KS, Zumaquero E, et al. . Distinct effector B cells induced by unregulated toll-like receptor 7 contribute to pathogenic responses in systemic lupus erythematosus. Immunity 2018; 49:725&#x2013;39.e6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6217820</ArticleId><ArticleId IdType="pubmed">30314758</ArticleId></ArticleIdList></Reference><Reference><Citation>Ong SWX, Fong S-W, Young BE, et al. . Persistent symptoms and association with inflammatory cytokine signatures in recovered coronavirus disease 2019 patients. Open Forum Infect Dis 2021; 8:ofab156.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8083585</ArticleId><ArticleId IdType="pubmed">34095336</ArticleId></ArticleIdList></Reference><Reference><Citation>Phetsouphanh C, Darley DR, Wilson DB, et al. . Immunological dysfunction persists for 8 months following initial mild-to-moderate SARS-CoV-2 infection. Nat Immunol 2022; 23:210&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">35027728</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y, Wang J, C L, et al. . IP-10 and MCP-1 as biomarkers associated with disease severity of COVID-19. Mol Med 2020; 26:97.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7594996</ArticleId><ArticleId IdType="pubmed">33121429</ArticleId></ArticleIdList></Reference><Reference><Citation>Khandaker GM, Pearson RM, Zammit S, Lewis G, Jones PB.. Association of serum interleukin 6 and C-reactive protein in childhood with depression and psychosis in young adult life: a population-based longitudinal study. JAMA Psychiatr 2014; 71:1121&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4561502</ArticleId><ArticleId IdType="pubmed">25133871</ArticleId></ArticleIdList></Reference><Reference><Citation>Wium-Andersen MK, &#xd8;rsted DD, Nielsen SF, Nordestgaard BG.. Elevated C-reactive protein levels, psychological distress, and depression in 73, 131 individuals. JAMA Psychiatr 2013; 70:176&#x2013;84.</Citation><ArticleIdList><ArticleId IdType="pubmed">23266538</ArticleId></ArticleIdList></Reference><Reference><Citation>Ortelli P, Ferrazzoli D, Sebastianelli L, et al. . Neuropsychological and neurophysiological correlates of fatigue in post-acute patients with neurological manifestations of COVID-19: insights into a challenging symptom. J Neurol Sci 2021; 420:117271.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7834526</ArticleId><ArticleId IdType="pubmed">33359928</ArticleId></ArticleIdList></Reference><Reference><Citation>Koralnik IJ, Tyler KL.. COVID-19: a global threat to the nervous system. Ann Neurol 2020; 88:1&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7300753</ArticleId><ArticleId IdType="pubmed">32506549</ArticleId></ArticleIdList></Reference><Reference><Citation>Lorkiewicz P, Waszkiewicz N.. Biomarkers of post-COVID depression. J Clin Med 2021; 10:4142.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8470902</ArticleId><ArticleId IdType="pubmed">34575258</ArticleId></ArticleIdList></Reference><Reference><Citation>Vlachoyiannopoulos PG, Magira E, Alexopoulos H, et al. . Autoantibodies related to systemic autoimmune rheumatic diseases in severely ill patients with COVID-19. Ann Rheum Dis 2020; 79:1661&#x2013;3.</Citation><ArticleIdList><ArticleId IdType="pubmed">32581086</ArticleId></ArticleIdList></Reference><Reference><Citation>Diao B, Wang C, Yingjun T, et al. . Reduction and functional exhaustion of T cells in patients with Coronavirus disease 2019 (COVID-19). Front Immunol 2020; 11:827.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7205903</ArticleId><ArticleId IdType="pubmed">32425950</ArticleId></ArticleIdList></Reference><Reference><Citation>Townsend L, Dyer AH, Naughton A, et al. . Longitudinal analysis of COVID-19 patients shows age-associated T cell changes independent of ongoing ill-health. Front Immunol 2021; 12:676932.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8138306</ArticleId><ArticleId IdType="pubmed">34025675</ArticleId></ArticleIdList></Reference><Reference><Citation>Varghese J, Sandmann S, Ochs K, et al. . Persistent symptoms and lab abnormalities in patients who recovered from COVID-19. Sci Rep 2021; 11:12775.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8211641</ArticleId><ArticleId IdType="pubmed">34140539</ArticleId></ArticleIdList></Reference><Reference><Citation>Jabeen R, Kaplan MH.. The symphony of the ninth: the development and function of Th9 cells. Curr Opin Immunol 2012; 24:303&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3368035</ArticleId><ArticleId IdType="pubmed">22365614</ArticleId></ArticleIdList></Reference><Reference><Citation>Orologas-Stavrou N, Politou M, Rousakis P, et al. . Peripheral blood immune profiling of convalescent plasma donors reveals alterations in specific immune subpopulations even at 2 months post SARS-CoV-2 infection. Viruses 2020; 13:26.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7824046</ArticleId><ArticleId IdType="pubmed">33375675</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>